These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39327962)

  • 61. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
    Shah NP; Guilhot F; Cortes JE; Schiffer CA; le Coutre P; Brümmendorf TH; Kantarjian HM; Hochhaus A; Rousselot P; Mohamed H; Healey D; Cunningham M; Saglio G
    Blood; 2014 Apr; 123(15):2317-24. PubMed ID: 24569263
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
    Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
    Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
    Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
    Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population.
    Morales-Chacón K; Bourlon C; Acosta-Medina AA; Bourlon MT; Aguayo A; Tuna-Aguilar E
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e299-e306. PubMed ID: 30905538
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
    Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
    Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
    Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
    Spencer A; Szydlo RM; Brookes PA; Kaminski E; Rule S; van Rhee F; Ward KN; Hale G; Waldmann H; Hows JM; Batchelor JR; Goldman JM
    Blood; 1995 Nov; 86(9):3590-7. PubMed ID: 7579468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan.
    Nakata K; Okawa S; Fuji S; Sato A; Morishima T; Tada Y; Inoue M; Hara J; Kawa K; Miyashiro I;
    Cancer Sci; 2021 Mar; 112(3):1150-1160. PubMed ID: 33428808
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Cause of death, survival, and prognostic factors in a series of 98 patients with chronic myeloid leukemia].
    Jonte F; Fernández-Fuertes F; Cecchini C; Luño E; Ordóñez A; Fernández C; Suárez P; Lausín A; Fernández J
    Sangre (Barc); 1992 Oct; 37(5):351-4. PubMed ID: 1293774
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
    Huang Q; Zhang XY; Li Y; Wang XM
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3049-53. PubMed ID: 24417926
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
    Griffin JD; Guerin A; Chen L; Macalalad AR; Luo J; Ionescu-Ittu R; Wu EQ
    Curr Med Res Opin; 2013 Jun; 29(6):623-31. PubMed ID: 23517347
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia.
    Huang J; Guan H
    Clin Lab; 2024 Jul; 70(7):. PubMed ID: 38965952
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
    Giona F; Putti MC; Micalizzi C; Menna G; Moleti ML; Santoro N; Iaria G; Ladogana S; Burnelli R; Consarino C; Varotto S; Tucci F; Messina C; Nanni M; Diverio D; Biondi A; Pession A; Locatelli F; Piciocchi A; Gottardi E; Saglio G; Foà R
    Br J Haematol; 2015 Aug; 170(3):398-407. PubMed ID: 25891192
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
    Ashariati A; Ugroseno S
    Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
    [TBL] [Abstract][Full Text] [Related]  

  • 77. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
    Jabbour E; Cortes J; Nazha A; O'Brien S; Quintas-Cardama A; Pierce S; Garcia-Manero G; Kantarjian H
    Blood; 2012 May; 119(19):4524-6. PubMed ID: 22431574
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [A long-term follow-up study of 82 children with acute myeloid leukemia].
    Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
    [No Abstract]   [Full Text] [Related]  

  • 80. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
    Quintás-Cardama A; Choi S; Kantarjian H; Jabbour E; Huang X; Cortes J
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):327-334.e8. PubMed ID: 24594142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.